Our submissions to recent treatment appraisals

Crohn's & Colitis UK work to ensure access to effective drugs and treatments for people with Crohn’s Disease and Ulcerative Colitis. We do this through submitting evidence to organisations such as the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) who produce treatment guidelines and appraise new drugs and therapies.

Submissions to recent appraisals are below. 

Ustekinumab (Stelara) 

For treating moderately to severely active Crohn’s in adults after prior therapy with conventional treatments such as cocorticosteroids and immunomodulators and/or TNFα (tumour necrosis factor-alpha) inhibitors like adalimumab (Humira), infliximab (Remicade, Inflectra, Remsima) or if patients are unable to use these therapies for medical reasons.

See the final comments.

NICE submission for ustekinumab (pdf)

News item (NICE recommendation)

SMC submission for ustekinumab (pdf)

Ferric maltol (Feraccru) 

For the treatment of iron deficiency anaemia in adults with Crohn's and Colitis. 

AWMSG submission for ferric maltol (pdf)

News item ferric maltol

SMC submission for ferric maltol (pdf)

Budesonide (Cortiment) 

For induction or remission in adult patients with mild to moderate active Colitis where 5 ASA treatment is not sufficient.

SMC submission for budesonide (pdf)

Tofacitinib (Xeljanz)

For treating moderately to severely active Colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment.

News item for tofacitinib

NICE guidelines

SMC submission for Tofacitinib 

Darvadstrocel (Alofisel)

For previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's. 

News item darvadstrocel

NICE guidelines

SMC submission for darvadstrocel